Phosphatidylserine inhibition of monoamine oxidase in platelets of schizophrenics. 1986

K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett

Phosphatidylserine (PS) has recently been reported to be a specific inhibitor of B-type monoamine oxidase (MAO-B). The effect of added PS liposomes on platelet MAO-B activity was examined in two schizophrenic groups (paranoid and a mixture of residual/undifferentiated) and in normal controls. PS was a potent partial-mixed-uncompetitive inhibitor of the platelet enzyme, whereas other phospholipids tested were without effect. The PS concentration required for 50% inhibition was significantly higher for the paranoid relative to the residual/undifferentiated group and controls. This correlated with a lower mean basal MAO-B activity in this group. Hill plots, as a measure of the concentration dependence of PS sensitivity, however, revealed a similarity between the two schizophrenic groups in regard to inhibitor binding properties. Mean Hill coefficients for both groups were significantly different from the controls. The results were consistent with an in vivo role for PS as an allosteric regulator of platelet MAO-B.

UI MeSH Term Description Entries
D008246 Lysophospholipids Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal. Lysophosphatidic Acids,Lysophospholipid,Acids, Lysophosphatidic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D010718 Phosphatidylserines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a SERINE moiety. Serine Phosphoglycerides,Phosphatidyl Serine,Phosphatidyl Serines,Phosphatidylserine,Phosphoglycerides, Serine,Serine, Phosphatidyl,Serines, Phosphatidyl
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006865 Hydrogenation Addition of hydrogen to a compound, especially to an unsaturated fat or fatty acid. (From Stedman, 26th ed) Hydrogenations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
February 1975, Nature,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
July 1975, Psychopharmacology bulletin,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
August 1986, Neuroscience letters,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
January 1980, Schizophrenia bulletin,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
January 1965, Annales medicinae experimentalis et biologiae Fenniae,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
June 1981, Archives of general psychiatry,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
November 1975, National Institute on Drug Abuse research monograph series,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
January 1981, Psychopharmacology,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
August 1994, Biochemical Society transactions,
K H Tachiki, and T D Buckman, and S Eiduson, and A S Kling, and J Hullett
January 1960, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!